Academic Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01) | Apply Online

Opportunity Summary:

The Academic Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01) funding opportunity (PAR-15-075) is an NIH grant program meant to push cancer-related diagnostic and treatment-enabling technologies out of the lab and closer to real-world use. The core idea is that progress happens faster when academic groups and industry partners work together in a coordinated way, so the FOA is built around formal partnerships that combine academic scientific expertise with industrial development, engineering, manufacturing, regulatory, and productization know-how. Projects are expected to be problem-driven, meaning applicants should start with a clearly defined cancer need and then build a translational plan that uses or advances a specific technology, assay, device, method, or system to address that need.

This FOA focuses on translation for preclinical or clinical molecular diagnosis and in vitro imaging, along with molecular imaging and related research resources that directly support these goals. NIH is not asking for early-stage discovery science here; instead, the emphasis is on taking something that already has a credible foundation and doing the work required to make it perform reliably in realistic settings. That can include improving or adapting existing commercially supported platforms, developing next-generation versions of existing tools, and doing the practical development steps that often block adoption, such as optimization, robustness testing, workflow integration, and performance validation. The announcement explicitly highlights support for quality assurance and quality control activities, validation and correlation studies, and quantitative imaging work, all of which are typical prerequisites for clinical confidence and broader deployment.

A key point in the FOA is how it defines innovation. Innovation is not framed as purely novel biology or a brand-new invention; it is framed as a coherent translational plan that delivers new or emerging capabilities into preclinical or clinical use where they are not yet widely employed. In other words, a project can be considered innovative if it credibly moves a technology into the hands of end users or enables a capability that clinicians or researchers do not currently have in routine practice, even if the underlying concept is not brand new. This makes the program well-suited for efforts that bridge the common gap between a promising prototype and a validated, usable system.

The required partnership structure is also central. Applications are expected to bring together an interdisciplinary, multi-institutional team operating as a strategic alliance, with a unified strategy and clear roles across the academic and industrial sides. The intent is that the partnership is not superficial; it should be organized around a shared development and translation roadmap with milestones that move the system toward practical deployment for the targeted cancer problem. Because real translation often requires testing under real conditions, the FOA allows and supports clinical trials, specifically those designed to test functionality and to optimize and validate performance of the proposed technology as part of the translation process.

At the same time, the FOA draws boundaries around what it will not support. It is not intended to pay for commercial-scale production, and it is not meant for basic research projects that do not put translation front and center. Applicants should therefore be prepared to show why their work is positioned at the development/translation stage, what remains to be done to make it usable and trustworthy in preclinical or clinical contexts, and how the academic-industry team is uniquely positioned to complete those steps.

Administratively, this is an R01 discretionary grant opportunity under NIH, categorized under health and education-related activities, and tied to CFDA numbers 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research). It does not require cost sharing or matching. The FOA was posted December 16, 2014, and the opportunity’s listed closing date was January 7, 2017, with an archive date of February 7, 2017, indicating it is no longer an active open solicitation in its original form, though it remains useful as a reference point for similar NIH translational partnership announcements. Eligibility is broad and includes many organization types across academia, nonprofit, for-profit (including but not limited to small businesses), and government entities, including U.S. and non-U.S. entities, minority-serving institutions, tribal organizations, and community-based or faith-based organizations, as long as the project structure fits the academic-industry partnership model and the work aligns with the translational scope described.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: NIAMS Skin Biology and Diseases Resource based Centers (P30)

Previous opportunity: Investigating New Approaches for Tobacco Surveillance Systems

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 15 075

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 15 075) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 15 075", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.